Lynn Anne Bristol

Array ( [id] => 19311595 [patent_doc_number] => 12037398 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Anti-VLA-4 antibodies having reduced effector function [patent_app_type] => utility [patent_app_number] => 15/734915 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 67 [patent_no_of_words] => 64655 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267495 [patent_doc_number] => 20190382481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => ANTI-CD33 ANTIBODIES, ANTI-CD33/ANTI-CD3 BISPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/418420 [patent_app_country] => US [patent_app_date] => 2019-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16418420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17286291 [patent_doc_number] => 11202829 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 16/411276 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 19117 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16411276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931135 [patent_doc_number] => 20200157201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => METHODS FOR TREATING OSTEOARTHRISTIS PAIN BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 16/410325 [patent_app_country] => US [patent_app_date] => 2019-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16410325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17997877 [patent_doc_number] => 11498971 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 16/406859 [patent_app_country] => US [patent_app_date] => 2019-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 33394 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16406859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611580 [patent_doc_number] => 20220153859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => GLYCOPHORIN A ANTIGEN-BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 17/052954 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15023469 [patent_doc_number] => 20190322739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => BISPECIFIC FORMAT SUITABLE FOR USE IN HIGH-THROUGH-PUT SCREENING [patent_app_type] => utility [patent_app_number] => 16/402097 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16402097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14746809 [patent_doc_number] => 20190256578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => Engineered Rabbit Antibody Variable Domains And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/402027 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16402027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717883 [patent_doc_number] => 11795214 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains [patent_app_type] => utility [patent_app_number] => 16/399424 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 15 [patent_no_of_words] => 10881 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16399424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360979 [patent_doc_number] => 20200016254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => Neoepitope vaccine and minnune stimulant combinations and methods [patent_app_type] => utility [patent_app_number] => 16/390946 [patent_app_country] => US [patent_app_date] => 2019-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16390946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15740639 [patent_doc_number] => 20200109207 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 16/387228 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16776538 [patent_doc_number] => 20210113615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => HETERODIMERIC INACTIVATABLE CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/046760 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -125 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14652803 [patent_doc_number] => 20190233530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/379844 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16379844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527295 [patent_doc_number] => 20200055953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => Method for Treating a GD2 Positive Cancer [patent_app_type] => utility [patent_app_number] => 16/375022 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19090994 [patent_doc_number] => 11952424 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-09 [patent_title] => Multivalent antibody [patent_app_type] => utility [patent_app_number] => 16/370346 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 60 [patent_no_of_words] => 37747 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16370346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15119623 [patent_doc_number] => 20190346444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/362940 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393391 [patent_doc_number] => 11242393 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Antibodies against MICA and/or MICB and uses thereof [patent_app_type] => utility [patent_app_number] => 16/362411 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 85 [patent_figures_cnt] => 114 [patent_no_of_words] => 64851 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738324 [patent_doc_number] => 12215142 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Antibody fragment degrading and removing abnormal TDP-43 [patent_app_type] => utility [patent_app_number] => 16/980667 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 6080 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534621 [patent_doc_number] => 20190202932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => ANTI- EGFR CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/352192 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14566949 [patent_doc_number] => 20190211081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => ANTIBODY CONSTANT REGION VARIANT [patent_app_type] => utility [patent_app_number] => 16/298032 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16298032 [rel_patent_id] =>[rel_patent_doc_number] =>)